Background-Thirty-five percent of pancreatic cancer patients have unresectable locally advanced pancreatic cancer (LAPC) at diagnosis. Several studies have evaluated systemic chemotherapy with FOLFIRINOX for patients with LAPC. We report a patient-level meta-analysis of LAPC patients treated with FOLFIRINOX as first-line treatment.
Introduction
Pancreatic cancer is the fourth leading cause of cancer-related death with only a 6% survival at 5 years. (1, 2) At the time of diagnosis, about 15% of patients have resectable disease (stage I or II), 35% locally advanced pancreatic cancer (LAPC, stage III), and 50% metastatic disease (stage IV). ( 3) The diagnosis of resectable disease and LAPC is determined by the extent of tumor contact with the superior mesenteric artery, celiac artery, superior mesenteric vein, and portal vein. The risk of a positive resection margin increases with increasing tumor contact of the arteries and/or veins. LAPC is considered unresectable because patients who underwent a resection with positive margin had the same overall survival (OS) as patients who did not undergo a resection.(4) Several definitions for LAPC have been proposed that vary mainly in the extent of tumor contact. The two commonly used criteria are from the National Comprehensive Cancer Network (NCCN, USA) and from the joint consensus conference of the Americas Hepato-Pancreato-Biliary Association (AHPBA), the Society of Surgical Oncology (SSO), and the Society for Surgery of the Alimentary Tract (SSAT). (5, 6) The NCCN and AHPBA/SSO/SSAT definitions for LAPC are summarized in table 1.
Systemic chemotherapy is the main treatment for patients with LAPC or metastatic disease. For decades 5-fluorouracil (5-FU) was the standard palliative treatment for pancreatic cancer. In 1997, a randomized controlled trial (RCT) including metastatic and LAPC patients showed an improved survival of 5·6 months for patients treated with gemcitabine versus 4·4 months with 5-FU (p=0·0025). (7) In 2011, an RCT (the PRODIGE 4/ACCORD 11 RCT) found a median OS of 11·1 months with FOLFIRINOX versus 6·8 months with gemcitabine (p< 0·0001) in patients with metastatic disease. (8) No RCT has been performed with FOLFIRINOX for LAPC patients. Many case series with FOLFIRINOX for LAPC patients have been published in the past four years, but the sample size of most studies was too small to draw definitive conclusions about efficacy and safety of FOLFIRINOX in LAPC patients. The aim of this paper was to perform a systematic review and patient-level meta-analysis to evaluate FOLFIRINOX as first-line treatment for patients diagnosed with LAPC.
Method
This review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and the Cochrane Handbook for Systematic Reviews of Interventions. (9, 10) It was registered at the University of York PROSPERO 2015 with registration number CRD42015017354.(11)
Selection criteria and search strategy
Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intravenous infusion of leucovorin (400 mg/m2) concomitantly with a 90-min intravenous infusion of irinotecan (180 mg/m2), followed by a bolus (400 mg/m2) and a 46-h continuous infusion (2,400 mg/m2) of 5-FU. The duration of a cycle is 2 weeks. (12) A systematic literature search was performed in Embase, Medline (ovidSP), Web of Science, Scopus, PubMed Publisher, Cochrane, and Google Scholar. The last search was run on July 2 nd , 2015. Search terms included: FOLFIRINOX, folinic acid, fluorouracil, irinotecan, oxaliplatin, pancreas cancer, and relevant variants thereof. No language or publication date restrictions were imposed. The grey literature was not accessed (i.e. literature that has not been formally published).(13) See the webappendix, page 1 for the detailed search strategy.
After removing duplicates, abstracts were independently reviewed by two authors (MS and BRB). Differences between authors were resolved by discussion. Abstracts were excluded if the record type was a case report, review, letter to the editor, or a conference abstract without full text. When eligibility criteria appeared to be met, the full text was retrieved for further evaluation. Full text studies were excluded if the study used a regimen other than FOLFIRINOX, used FOLFIRINOX in combination with other chemotherapy at the same time, investigated FOLFIRINOX not as first-line treatment, did not include LAPC patients, was a review, or if the same patient cohort was presented in another study.
Outcome
The primary outcome measure was OS. Secondary outcomes were progression free survival (PFS), grade 3 or 4 adverse events, percentage of (chemo)radiation, percentage of resection after FOLFIRINOX, and percentage of R0 resection.
Two authors (MS and BRB) independently extracted information from the full texts using a predefined data extraction sheet. Disagreements were resolved by discussion.
The following study details were extracted: study characteristics (first author, year of publication, study design), study population (total number of patients analyzed, patient groups, tumor stage, location, and local extend of the disease), diagnostic work-up (staging laparoscopy), type of intervention (FOLFIRINOX regimen and number of administered cycles, percentage of (chemo)radiation, resection, and R0 resection), and outcome (duration of follow-up, OS, PFS, grade 3 or 4 adverse events). Updated patient-level data on OS and PFS were obtained from the authors of all studies presenting survival outcomes. Percentage of (chemo)radiation and resection were obtained from the studies and are not patient-level data.
Patient-level data collection
Patient-level data on OS and PFS were obtained from the authors of all studies presenting survival outcomes. The authors of the original studies updated and checked their patientlevel data. No patient-level data was missing on survival outcomes. Results other than survival outcomes (e.g., toxicity data or percentage of (chemo)radiation and resection) are not based on patient-level data.
Statistical analysis To ascertain the risk of bias, each study was assessed (MS) using the scoring system developed by the Critical Appraisal Skill Program (CASP). The CASP tool is 
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Author Manuscript a critical appraisal tool for observational studies to assess the methodological quality of the individual studies. (14) Publication bias was assessed with a funnel plot. (15) Survival outcomes (OS and PFS) were evaluated with the Kaplan-Meier method using patient-level data in SPSS version 21.(16) Studies presenting only LAPC patients who underwent a resection after FOLFIRINOX were excluded from survival analysis to avoid selection bias. A post hoc subgroup analysis of the (patient-level) median OS of studies with at least 20 LAPC patients was conducted.
Grade 3 or 4 adverse events were calculated as number of events per 100 patients and pooled in random effects models using the statistical MedCalc package (version 16·2). (17) Pooled percentages of (chemo)radiation, resection, and R0 were calculated in random effects models using the statistical MedCalc package (version 16·2).(17) Random (instead of fixed) effects models were used because of anticipated heterogeneity in LAPC definitions across studies. (18) We tested for heterogeneity with visual inspection of the forest plots and used I 2 as measure of consistency across studies. A Spearman's correlation was calculated (as post hoc analyses) across studies between (chemo)radiation and OS, resection and OS, and the median number of administered FOLFIRINOX cycles and OS.
No funding has been received for this work. The corresponding author had full access to all of the data and the final responsibility to submit for publication.
Results

Studies
The search criteria resulted in 840 potentially eligible studies. After screening of the abstracts, 30 studies were selected for full text assessment, of which 13 studies fulfilled the inclusion criteria. (12, (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) The excluded studies are presented in the webappendix, pages 2 and 3. Figure 1 presents the flowchart.
Study characteristics
One study was a prospective non-randomized phase II study, (12) one was a prospective cohort study, (26) and the other eleven studies were retrospective cohort studies. (19) (20) (21) (22) (23) (24) (25) (27) (28) (29) (30) Three studies used the NCCN criteria (22, 29, 30) , and three studies used the AHPBA/SSO/SSAT criteria (23, 24, 28) to define LAPC. The other seven studies determined LAPC based on multidisciplinary review board or retrospective evaluation of pretreatment imaging. (12, (19) (20) (21) (25) (26) (27) Only three studies presented a patient cohort including only LAPC patients. (22, 26, 30 ) None of the studies described a staging laparoscopy as part of the diagnostic work-up. Study characteristics are presented in Table 2 . The study quality assessments and funnel plot are presented in the webappendix, pages 4 and 5.
Patient characteristics
The thirteen studies included a total of 689 patients, of whom 355 patients had LAPC. All other patients had (borderline) resectable, metastatic, or recurrent disease. The total population consisted of 53% male patients and the median age ranged from 56 to 66 years ( Table 2) . Figure 2 presents the survival curves of all individual studies as well as the pooled survival curves for OS and PFS.
Two studies used a dose modification of the FOLFIRINOX dose described in the PRODIGE-4 trial.(12) Median OS was 21.2 months in the study that did not give a bolus of 5-FU (20) and median OS was 26.0 months in the study with 80% dose intensity. (30) The median number of administered cycles was reported in nine of eleven studies and ranged from 3 to 11 cycles, where each cycle was 2 weeks. (12, 20-22, 24-27, 30) No significant correlation was found across studies between the median number of cycles and median OS (p=0·95) (webappendix , page 6).
Toxicity data
In eight studies, the adverse events were reported using the Common Terminology Criteria for Adverse Events (CTCAE). Two studies did not state which criteria were used. (19, 22) Three studies did not report toxicity data. (19, 28, 29) A total of 490 patients in 10 studies were analyzed for grade 3 or 4 adverse events. Of these ten studies, eight studies used the full dose of FOLFIRINOX as described in the PRODIGE-4 trial.(12) Two studies had a modification of this dose with one study not giving a bolus of 5-FU (20) and another study with 80% dose intensity. (30) No deaths attributed to FOLFIRINOX were reported. In 10 studies representing 490 patients, 296 Grade 3 or 4 adverse events were reported (i.e. 60·4 events per 100 patients). All grade 3 or 4 adverse events are presented in table 4. The pooled event rates per 100 patients for grade 3 or 4 adverse events are presented in forest plots (Figure 4 ). The pooled rates per 100 patients were 19·6 (95% CI: 10·9-29·9, I 2 = 83%) for neutropenia, 5·9 (95% CI: 2·9-9·8, I 2 = 53%) for thrombocytopenia, 8·2 (95% CI: 5·0 -12·1, I 2 = 36%) for diarrhea, 8·8 (95% CI: 5·0 -13·5, I 2 =36%) for vomiting, and 11·7 (95% CI: 7·3 -17·0, I 2 = 51%) for fatigue.
The use of granulocyte-colony stimulating factor (G-CSF) was reported in eight studies representing 368 patients. (12, (20) (21) (22) (24) (25) (26) (27) Of those 368 patients, 269 (73·1%) received G-CSF. Four studies gave G-CSF as primary prophylaxis. (20, 22, 25, 26) one study as secondary prophylaxis (12) , and three studies left it to the discretion of the treating physician. 
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Subsequent treatment
Results on subsequent treatments were not based on patient-level data. The percentage of (chemo)radiation ranged from 31·2% to 100·0% across studies. (Chemo)radiation was reported in eight studies representing 271 patients of whom 154 patients received (chemo)radiation (56·8%) after FOLFIRINOX. (19, 20, 22-24, 26, 29, 30) The pooled percentage of (chemo)radiation in a random effects model was 63·5% (95% CI: 43·3% -81·6%, I 2 = 90%). The modalities were stereotactic body radiotherapy (SBTR) in three studies (20, 23, 29) , chemoradiation in three studies (22, 24, 30) , and conventional radiation therapy in two studies. (19, 26) No significant association was found across studies between the percentage of (chemo)radiation and OS (p=0·12) (webappendix, page 6).
The percentage of resection for LAPC ranged from 0·0% to 42·9% across studies. The percentage of margin negative (i.e. R0) resection of patients who underwent a resection ranged from 50% to 100% (Table 5 ). Four studies did not report the percentage of an R0 resection. (19, 21, 25, 27) One study only presented those patients that underwent a resection after FOLFIRINOX and was not included in the analysis for the percentage of resection. (28) In twelve studies, 91 of 325 patients (28·0%) underwent a resection after FOLFIRINOX for LAPC. The pooled percentage of resection in a random effects model was 25·9% (95% CI: 20·2% -31·9%, I 2 = 24%). Resection margin status was missing in 10 patients. An R0 resection was reported in 60 out of 81 patients (74·1%). The pooled percentage of R0 resection in a random effects model was 78·4% (95% CI: 60·2% -92·2%, I 2 = 64%) ( Figure  4 ). No significant correlation was found across studies between percentage of resection and OS (p=0·39) (webappendix, page 7).
DISCUSSION
We found thirteen studies that assessed FOLFIRINOX as first-line treatment for LAPC. The patient-level meta-analysis of eleven studies representing 315 patients found a median PFS of 15·0 months and a median OS of 24·2 months. We found that 63·5% of patients received (chemo)radiation after FOLFIRINOX. Across studies no significant correlation was found between the use of (chemo)radiation and OS. However, this analysis was not performed at the patient-level. The rationale of (chemo)radiation is that about 30% of pancreatic cancer patients die from local progression in the absence of metastatic disease.(40) LAPC patients who do not develop metastatic disease during systemic treatment might benefit from local control of the tumor with (chemo)radiation. The role of (chemo)radiation in LAPC is still unclear due to conflicting results.(41) In a phase III trial (LAP 07), 442 patients were randomized to receive 4 months of gemcitabine with or without erlotinib. Patients with controlled disease after 4 months were then randomized to either continued systemic chemotherapy or chemoradiation. The median survival was 16·4 months for continuing chemotherapy and 15·3 months for proceeding to chemoradiation (HR: 1·03; 95% CI: 0·79-1·34; p=0·83).(42) Two ongoing RCTs are evaluating the benefit of (chemo)radiation after induction chemotherapy.(43, 44) Stereotactic body radiation therapy (SBRT) has shown promising results in tumor control in patients with LAPC. (45, 46) The feasibility and efficacy of SBRT following induction FOLFIRINOX is being evaluated in clinical trials. (47, 48) We found that in 25·9% of LAPC patients underwent a resection after FOLFIRINOX, of whom 78·4% had an R0 resection. Considerable heterogeneity across studies in the percentage of resection is explained by lack of consensus in the literature on selecting patients for resection after FOLFIRINOX. (49) No significant correlation was found across studies between the percentage of resection and OS. However, this analysis was not performed at the patient level. Future studies should evaluate whether resection after FOLFIRINOX improves OS or quality of life, and how to select patients for resection.
The main limitation of this patient-level meta-analysis is that all studies were nonrandomized and most studies had a retrospective design. Retrospective studies are known to underreport toxicity outcomes. Moreover, PFS may be biased due to the lack of standardized on-treatment imaging in retrospective studies. Secondly, the results of this meta-analysis may be biased because studies used different definitions for LAPC; three studies used the NCCN criteria (22, 29, 30) , three studies used the AHPBA/SSO/SSAT criteria, (23, 24, 28) and the other seven studies diagnosed LAPC based on multidisciplinary review board or retrospective evaluation of pretreatment imaging. (12, (19) (20) (21) (25) (26) (27) The NCCN and AHPBA/SSO/SSAT definitions for LAPC vary mainly in the extent of vascular involvement ( 
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Author Manuscript Table 2 Study characteristics 39 (14) 29 (10) 23 (8) 20 (7) 16 (6) 15 (5) 14 (5) 13 (5) 10 ( Cells were left empty when a study did not report on an adverse event. Totals differ slightly from pooled rates in Figure 4 that were calculated using random effects modeling.
Lancet Oncol. Author manuscript; available in PMC 2017 July 26.
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